Nature Reviews Clinical Oncology最新文献_第2页

Lack of benefit from extended lymphadenectomy in muscle-invasive bladder cancer 肌肉浸润性膀胱癌的扩大淋巴结切除术缺乏益处

IF 81.1 1区医学

Nature Reviews Clinical Oncology Pub Date : 2024-10-23 DOI: 10.1038/s41571-024-00961-4

Diana Romero

引用次数: 0

The TOPGEAR trial — is chemoradiotherapy no longer a component of multidisciplinary care for gastric cancer? TOPGEAR 试验--化放疗是否不再是胃癌多学科治疗的组成部分？

IF 78.8 1区医学

Nature Reviews Clinical Oncology Pub Date : 2024-10-21 DOI: 10.1038/s41571-024-00960-5

Brian Badgwell

引用次数: 0

MRI-based stratification reduces the risk of overdiagnosis of prostate cancer 基于磁共振成像的分层可降低前列腺癌过度诊断的风险

IF 81.1 1区医学

Nature Reviews Clinical Oncology Pub Date : 2024-10-16 DOI: 10.1038/s41571-024-00957-0

Peter Sidaway

引用次数: 0

Author Correction: Neoadjuvant immunotherapy for dMMR and pMMR colorectal cancers: therapeutic strategies and putative biomarkers of response 作者更正：针对dMMR和pMMR结直肠癌的新辅助免疫疗法：治疗策略和反应的假定生物标志物

IF 81.1 1区医学

Nature Reviews Clinical Oncology Pub Date : 2024-10-07 DOI: 10.1038/s41571-024-00955-2

Christopher J. M. Williams, Allyson M. Peddle, Pashtoon M. Kasi, Jenny F. Seligmann, Campbell S. Roxburgh, Gary W. Middleton, Sabine Tejpar

引用次数: 0

The high costs of anticancer therapies in the USA: challenges, opportunities and progress 美国抗癌疗法的高昂成本：挑战、机遇与进步

IF 81.1 1区医学

Nature Reviews Clinical Oncology Pub Date : 2024-10-04 DOI: 10.1038/s41571-024-00948-1

Shelley A. Jazowski, Rahul K. Nayak, Stacie B. Dusetzina

{"title":"The high costs of anticancer therapies in the USA: challenges, opportunities and progress","authors":"Shelley A. Jazowski, Rahul K. Nayak, Stacie B. Dusetzina","doi":"10.1038/s41571-024-00948-1","DOIUrl":"10.1038/s41571-024-00948-1","url":null,"abstract":"The USA spent $99 billion on orally administered and clinician-administered anticancer therapies (excluding supportive care) in 2023 and spending is projected to increase to $180 billion by 2028. This increased spending on anticancer therapies largely reflects the high launch prices of novel therapeutics and increases in the prices of existing products, even in the absence of new evidence of clinical benefit or changes in use. Consequently, high prices have impeded Americans’ access to and affordability of necessary anticancer therapies and thus increased their risk of cost-related non-adherence, cancer recurrence and mortality. To address the rising prices and concerns regarding Americans’ spending on anticancer therapies, state and federal governments have, over the past decade, enacted legislation that caps out-of-pocket spending, expands subsidies and requires drug price negotiations. In this Perspective, we summarize US policies aimed to lower the costs of anticancer therapies, discuss the implications of such reforms and propose additional solutions needed to reduce costs and increase value. The high cost of anticancer drugs is a problem worldwide that impairs access to treatment. These high costs are particularly notable in the USA, where the prices of cancer drugs are often double those of the same drugs in other economically developed countries. In this Perspective, the authors describe the origins and scale of this problem, and summarize the various state-level and federal-level interventions designed to reduce the costs of anticancer drugs, and thus improve access for patients.","PeriodicalId":19079,"journal":{"name":"Nature Reviews Clinical Oncology","volume":"21 12","pages":"888-899"},"PeriodicalIF":81.1,"publicationDate":"2024-10-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142374140","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Reflecting on the past 20 years in oncology 回顾过去 20 年的肿瘤学历程

IF 81.1 1区医学

Nature Reviews Clinical Oncology Pub Date : 2024-10-01 DOI: 10.1038/s41571-024-00950-7

引用次数: 0

Two decades of advances in clinical oncology — lessons learned and future directions 临床肿瘤学二十年的进步--经验教训与未来方向

IF 81.1 1区医学

Nature Reviews Clinical Oncology Pub Date : 2024-10-01 DOI: 10.1038/s41571-024-00945-4

Susana Banerjee, Christopher M. Booth, Eduardo Bruera, Markus W. Büchler, Alexander Drilon, Terry J. Fry, Irene M. Ghobrial, Luca Gianni, Rakesh K. Jain, Guido Kroemer, Josep M. Llovet, Georgina V. Long, Klaus Pantel, Kathy Pritchard-Jones, Howard I. Scher, Josep Tabernero, Ralph R. Weichselbaum, Michael Weller, Yi-Long Wu

引用次数: 0

From the ESMO Congress 2024 来自 2024 年 ESMO 大会

IF 81.1 1区医学

Nature Reviews Clinical Oncology Pub Date : 2024-09-30 DOI: 10.1038/s41571-024-00954-3

David Killock

引用次数: 0

Adding perioperative durvalumab to neoadjuvant chemotherapy provides benefit in MIBC 在新辅助化疗中加入围手术期杜瓦单抗可为MIBC患者带来益处

IF 81.1 1区医学

Nature Reviews Clinical Oncology Pub Date : 2024-09-26 DOI: 10.1038/s41571-024-00951-6

Diana Romero

引用次数: 0

Molecular imaging supports the development of multispecific cancer antibodies 分子成像支持多特异性癌症抗体的开发

IF 81.1 1区医学

Nature Reviews Clinical Oncology Pub Date : 2024-09-26 DOI: 10.1038/s41571-024-00946-3

Claudia A. J. van Winkel, Frank R. Pierik, Adrienne H. Brouwers, Derk Jan A. de Groot, Elisabeth G. E. de Vries, Marjolijn N. Lub-de Hooge

{"title":"Molecular imaging supports the development of multispecific cancer antibodies","authors":"Claudia A. J. van Winkel, Frank R. Pierik, Adrienne H. Brouwers, Derk Jan A. de Groot, Elisabeth G. E. de Vries, Marjolijn N. Lub-de Hooge","doi":"10.1038/s41571-024-00946-3","DOIUrl":"10.1038/s41571-024-00946-3","url":null,"abstract":"Multispecific antibodies are engineered antibody derivatives that can bind to two or more distinct epitopes or antigens. Unlike mixtures of monospecific antibodies, the binding properties of multispecific antibodies enable two specific molecules to be physically linked, a characteristic with important applications in cancer therapy. The field of multispecific antibodies is highly dynamic and expanding rapidly; to date, 15 multispecific antibodies have been approved for clinical use, of which 11 were approved for oncological indications, and more than 100 new antibodies are currently in clinical development. Nevertheless, substantial challenges limit the applications of multispecific antibodies in cancer therapy, particularly inefficient targeting of solid tumours and substantial adverse effects. Both PET and single photon emission CT imaging can reveal the biodistribution and complex pharmacology of radiolabelled multispecific antibodies. This Review summarizes the insights obtained from preclinical and clinical molecular imaging studies of multispecific antibodies, focusing on their structural properties, such as molecular weight, shape, target specificity, affinity and avidity. The opportunities associated with use of molecular imaging studies to support the clinical development of multispecific antibody therapies are also highlighted. Multispecific antibody constructs that bind several distinct targets can connect cells and/or simultaneously target multiple molecules. Here, Lub-de Hooge et al. discuss the varied contributions of molecular imaging to multispecific antibody design, drug development and optimization, including evaluations of antibody biodistribution and pharmacological complexity.","PeriodicalId":19079,"journal":{"name":"Nature Reviews Clinical Oncology","volume":"21 12","pages":"852-866"},"PeriodicalIF":81.1,"publicationDate":"2024-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142321319","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0